Lupin Limited has submitted to the Exchange, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin reported consolidated revenue of ₹71,675 million for Q3 FY26, up 24.3% year-on-year, with 9M FY26 revenue at ₹204,834 million, up 20.2% YoY. Consolidated profit after tax rose 29.9% YoY in Q3 to ₹11,105 million, and 52.4% YoY for 9M FY26 to ₹38,468 million. The company booked exceptional charges of ₹4,266 million in Q3, including a ₹4,494 million (USD 50 million) provision for US antitrust class-action lawsuits and a ₹1,348 million (USD 15 million) provision toward the Astellas/Mirabegron settlement. These were partially offset by a ₹6,590 million gain booked in Q2 from the slump-sale transfer of its OTC and API R&D businesses to subsidiaries. On the M&A front, Lupin agreed to acquire Dutch firm VISUfarma for EUR 190 million (pending) and completed the acquisition of UK-based Renascience Pharma for ₹1,362 million. Statutory auditor B S R & Co. LLP issued an unqualified limited review report on both sets of results.
Strong top-line growth of over 20% on a consolidated basis signals healthy demand momentum, but the Q3 bottom line was hit by large one-time legal and settlement provisions, which may temper near-term earnings sentiment despite the robust underlying business performance.